EGF, FGF, VEGF, and BPC 157, their presentation along with injuries, and a healing commonality, providing their implementation in both gastrointestinal
The seven peptides come in different names and are often administered by people themselves or by injectors at longevity or wellness practices as so-called stacks or multiple peptides administered simultaneously or in succession
Most protocols recommend splitting the difference at 28 days maximum
In a Phase II trial in ulcerative colitis, BPC-157 (also referred to by a code like PL 14736) reportedly helped induce remission of the disease and was noted to be well-tolerated with no side effects
Patients with inflammatory bowel disease who are already stable on approved biologic therapy (adalimumab, vedolizumab, ustekinumab) should not substitute BPC-157 for disease-modifying therapy